CDCP1在恶性肿瘤中的研究进展
The Research Progress of CDCP1 in Malignant Tumors
DOI: 10.12677/acm.2025.151202, PDF,   
作者: 姚泓哲, 杨林瀛*：承德医学院附属医院呼吸与危重症医学科，河北 承德
关键词: CDCP1；恶性肿瘤；研究进展；CDCP1； Malignant Tumor； Tumor Metastasis
摘要: CUB结构域包含蛋白1 (CUB domain containing protein 1, CDCP1)作为I型跨膜蛋白的一种，位于关键的致癌和肿瘤转移级联信号通路的连接点，通过启动或激活信号通路，促进肿瘤细胞生长、转移。CDCP1在多种恶性肿瘤如乳腺癌、前列腺癌、卵巢癌、肺癌等中高度表达，并与其预后相关，是目前诊断恶性肿瘤的重要生物标志物。本文综述了CDCP1的结构、作用机制及在不同恶性肿瘤中的研究进展。
Abstract: CDCP1 is a type I transmembrane protein located at the junction of key carcinogenesis and tumor metastasis signaling cascades, which promotes tumor cell growth and metastasis by initiating or activating signaling pathways. CDCP1, highly expressed in a variety of malignant tumors, is associated with the prognosis of malignant tumors, and is an important biomarker for the diagnosis of malignant tumors. In this review, the structure, mechanism of action and research progress of CDCP1 in different malignant tumors were reviewed.
文章引用：姚泓哲, 杨林瀛. CDCP1在恶性肿瘤中的研究进展[J]. 临床医学进展, 2025, 15(1): 1512-1517. https://doi.org/10.12677/acm.2025.151202

参考文献

[1] 曹梦迪, 陈万青. GLOBOCAN 2022全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2024, 16(6): 1-5.
[2] Turdo, F., Bianchi, F., Gasparini, P., Sandri, M., Sasso, M., De Cecco, L., et al. (2016) CDCP1 Is a Novel Marker of the Most Aggressive Human Triple-Negative Breast Cancers. Oncotarget, 7, 69649-69665. [Google Scholar] [CrossRef] [PubMed]
[3] Wright, H.J., Hou, J., Xu, B., Cortez, M., Potma, E.O., Tromberg, B.J., et al. (2017) CDCP1 Drives Triple-Negative Breast Cancer Metastasis through Reduction of Lipid-Droplet Abundance and Stimulation of Fatty Acid Oxidation. Proceedings of the National Academy of Sciences of the United States of America, 114, E6556-E6565. [Google Scholar] [CrossRef] [PubMed]
[4] Wright, H.J., Police, A.M. and Razorenova, O.V. (2016) Targeting CDCP1 Dimerization in Triple-Negative Breast Cancer. Cell Cycle, 15, 2385-2386. [Google Scholar] [CrossRef] [PubMed]
[5] Urabe, F., Kosaka, N., Yamamoto, Y., Ito, K., Otsuka, K., Soekmadji, C., et al. (2023) Metastatic Prostate Cancer‐derived Extracellular Vesicles Facilitate Osteoclastogenesis by Transferring the CDCP1 Protein. Journal of Extracellular Vesicles, 12, e12312. [Google Scholar] [CrossRef] [PubMed]
[6] Alajati, A., D’Ambrosio, M., Troiani, M., Mosole, S., Pellegrini, L., Chen, J., et al. (2020) CDCP1 Overexpression Drives Prostate Cancer Progression and Can Be Targeted in Vivo. Journal of Clinical Investigation, 130, 2435-2450. [Google Scholar] [CrossRef] [PubMed]
[7] Harrington, B.S., He, Y., Khan, T., Puttick, S., Conroy, P.J., Kryza, T., et al. (2020) Anti-CDCP1 Immuno-Conjugates for Detection and Inhibition of Ovarian Cancer. Theranostics, 10, 2095-2114. [Google Scholar] [CrossRef] [PubMed]
[8] Kong, L., Xu, F., Yao, Y., Gao, Z., Tian, P., Zhuang, S., et al. (2023) Ascites-Derived CDCP1+ Extracellular Vesicles Subcluster as a Novel Biomarker and Therapeutic Target for Ovarian Cancer. Frontiers in Oncology, 13, Article 1142755. [Google Scholar] [CrossRef] [PubMed]
[9] Murakami, Y., Kusakabe, D., Watari, K., Kawahara, A., Azuma, K., Akiba, J., et al. (2022) AXL/CDCP1/SRC Axis Confers Acquired Resistance to Osimertinib in Lung Cancer. Scientific Reports, 12, Article No. 8983. [Google Scholar] [CrossRef] [PubMed]
[10] Nam, Y., Choi, C., Park, Y.S., Jung, H., Hwang, H.S., Lee, J.C., et al. (2022) CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 11, Article 341. [Google Scholar] [CrossRef] [PubMed]
[11] Wortmann, A., He, Y., Deryugina, E.I., Quigley, J.P. and Hooper, J.D. (2009) The Cell Surface Glycoprotein CDCP1 in Cancer—Insights, Opportunities, and Challenges. IUBMB Life, 61, 723-730. [Google Scholar] [CrossRef] [PubMed]
[12] Khan, T., Kryza, T., Lyons, N.J., He, Y. and Hooper, J.D. (2021) The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention. Cancer Research, 81, 2259-2269. [Google Scholar] [CrossRef] [PubMed]
[13] Khan, T., Lyons, N.J., Gough, M., Kwah, K.K.X., Cuda, T.J., Snell, C.E., et al. (2022) CUB Domain-Containing Protein 1 (CDCP1) Is a Rational Target for the Development of Imaging Tracers and Antibody-Drug Conjugates for Cancer Detection and Therapy. Theranostics, 12, 6915-6930. [Google Scholar] [CrossRef] [PubMed]
[14] Uekita, T., Fujii, S., Miyazawa, Y., Iwakawa, R., Narisawa-Saito, M., Nakashima, K., et al. (2014) Oncogenic Ras/Erk Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis. Molecular Cancer Research, 12, 1449-1459. [Google Scholar] [CrossRef] [PubMed]
[15] Qi, X., Gao, J., Li, Z., Zhang, G., Li, J., Fu, Y., et al. (2022) CDCP1: A Promising Diagnostic Biomarker and Therapeutic Target for Human Cancer. Life Sciences, 301, Article ID: 120600. [Google Scholar] [CrossRef] [PubMed]
[16] 刘家琪. 神经胶质瘤临床预后分析及CDCP1对其EMT调控机制研究[D]: [硕士学位论文]. 海口: 海南医学院, 2023.
[17] 雷少元, 郑荣寿, 张思维, 等. 乳腺癌发病率和死亡率的全球模式: 一项基于人群的2000-2020年肿瘤登记数据分析研究[J]. 癌症, 2022, 41(7): 324-335.
[18] 朱佳钰, 张清媛. 肿瘤微环境与乳腺癌HER2靶向治疗耐药研究进展[J]. 现代肿瘤医学, 2024, 32(15): 2909-2914.
[19] Alajati, A., Guccini, I., Pinton, S., Garcia-Escudero, R., Bernasocchi, T., Sarti, M., et al. (2015) Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer. Cell Reports, 11, 564-576. [Google Scholar] [CrossRef] [PubMed]
[20] Chopra, S., Trepka, K., Sakhamuri, S., Carretero-González, A., Zhu, J., Egusa, E., et al. (2023) Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clinical Cancer Research, 29, 1232-1242. [Google Scholar] [CrossRef] [PubMed]
[21] Yang, L., Dutta, S.M., Troyer, D.A., Lin, J.B., Lance, R.A., Nyalwidhe, J.O., et al. (2015) Dysregulated Expression of Cell Surface Glycoprotein CDCP1 in Prostate Cancer. Oncotarget, 6, 43743-43758. [Google Scholar] [CrossRef] [PubMed]
[22] 黄山高, 吴月玲, 张颖. 瞄准未来: 卵巢癌靶向治疗的新进展[J]. 实用医学杂志, 2024, 40(14): 1901-1907.
[23] Dong, Y., He, Y., de Boer, L., Stack, M.S., Lumley, J.W., Clements, J.A., et al. (2012) The Cell Surface Glycoprotein CUB Domain-Containing Protein 1 (CDCP1) Contributes to Epidermal Growth Factor Receptor-Mediated Cell Migration. Journal of Biological Chemistry, 287, 9792-9803. [Google Scholar] [CrossRef] [PubMed]
[24] He, Y., Wu, A.C., Harrington, B.S., Davies, C.M., Wallace, S.J., Adams, M.N., et al. (2015) Elevated CDCP1 Predicts Poor Patient Outcome and Mediates Ovarian Clear Cell Carcinoma by Promoting Tumor Spheroid Formation, Cell Migration and Chemoresistance. Oncogene, 35, 468-478. [Google Scholar] [CrossRef] [PubMed]
[25] 支修益, 师建国, 田艳涛, 等. 《2022年中国肺癌患者生存质量白皮书》要点解读[J]. 中国胸心血管外科临床杂志, 2023, 30(8): 1083-1088.
[26] Dagnino, S., Bodinier, B., Guida, F., Smith-Byrne, K., Petrovic, D., Whitaker, M.D., et al. (2021) Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer. Cancer Research, 81, 3738-3748. [Google Scholar] [CrossRef] [PubMed]
[27] Chiu, K., Lin, Y., Kuo, T., Lo, C., Huang, Y., Chang, H., et al. (2017) ADAM9 Enhances CDCP1 by Inhibiting Mir-1 through EGFR Signaling Activation in Lung Cancer Metastasis. Oncotarget, 8, 47365-47378. [Google Scholar] [CrossRef] [PubMed]

为你推荐